SGMT Stock Forecast & Price Target

Sagimet Biosciences is supported by denifanstat’s strong and durable acne data, where IGA success improved from about 37% at Week 12 to 58% at Week 52, while total, inflammatory, and non-inflammatory lesion reductions deepened to 73%, 78%, and 68%, respectively. The clean long-term safety profile, with no evidence of cumulative tolerability issues and no discontinuations due to adverse events, strengthens the case for chronic once-daily use and supports a potential first-line oral role ahead of antibiotics. With AURORA set to enroll about 800 patients and include a 40-week extension, the company has a compelling near-term clinical catalyst backed by a differentiated FASN mechanism and additional optionality from TVB-3567 and the topical program.

Sagimet Biosciences is viewed negatively because, despite a clean safety profile through 52 weeks and no denifanstat-related Grade 3/4 events or treatment-related serious AEs, the company still faces substantial clinical, regulatory, and commercial execution risk. The acne program remains unproven at scale in a broader population, with key uncertainties around durability, adolescent inclusion, and whether the upcoming global Phase 3 in 2H26 can replicate earlier success through a potential YE27 readout. Financially, it is expected to continue incurring net losses at least until commercialization and likely through the early launch phase, while the need for additional capital raises raises dilution risk and the stock’s downside risk.